Biotech Pharma
12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis
SYDNEY, Australia, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical
company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the Phase 3
clinical trial evaluating the long term safety of Bronchitol in subjects with
bronchiectasis has... more
Telik Announces Diabetes License Agreement With ReceptorBio
PALO ALTO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Telik, Inc.
(Nasdaq: TELK) announced today that it has entered into a license agreement
with ReceptorBio, Inc. which would enable ReceptorBio to develop and
commercialize Telik's oral small molecule... more
ReceptorBio Announces Diabetes License Agreement With Telik
FOSTER CITY, Calif., Aug. 19 /PRNewswire-FirstCall/ -- ReceptorBio, Inc.
announced today that it has entered into a license agreement with Telik, Inc.
(Palo Alto, CA) (Nasdaq: TELK) that would enable ReceptorBio to develop and
commercialize Telik's... more
|
Multi-Cultural
MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
UNION CITY, Calif. and SHANGHAI, China, Aug. 18 /PRNewswire-FirstCall/ --
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company
developing next-generation antibiotics, today announced the nomination of MRX-
I as its first preclinical... more
Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
SHENZHEN, China, Aug. 15 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical
International Limited (NYSE: MR), a leading developer, manufacturer and
marketer of medical devices worldwide announced today that Mindray will be
attending the Morgan Stanley... more
AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
SINGAPORE, Aug. 15 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today
announced an innovative new partnership with the National Cancer Centre
Singapore (NCCS) and the National University Hospital (NUH) to develop
anti-cancer compounds. The... more
|